MARKET

ENTXW

ENTXW

ENTERA BIO
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4000
+0.0400
+11.11%
Closed 16:00 05/18 EDT
OPEN
0.3600
PREV CLOSE
0.3600
HIGH
0.4001
LOW
0.3322
VOLUME
15.28K
TURNOVER
--
52 WEEK HIGH
1.800
52 WEEK LOW
0.0526
MARKET CAP
--
P/E (TTM)
-0.7361
1D
5D
1M
3M
1Y
5Y
BRIEF-Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
reuters.com · 03/11 13:57
BRIEF-Entera Bio Announces Publication Of Phase 2 Hypoparathyroidism Study In The Journal Of Bone And Mineral Research
reuters.com · 02/25 14:40
BRIEF-Entera Bio Initiates New Research Program For Oral Glp-2
reuters.com · 02/08 13:51
BRIEF-Entera Bio Ltd Provides Update On Phase 2 Clinical Trial Of Eb613 In Postmenopausal Women With Osteoporosis
* ENTERA BIO LTD PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF EB613 IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
Reuters · 07/07/2020 12:42
BRIEF-Entera Bio Files For Shelf Of Upto 9.6 Mln Shares By Selling Stockholders
* ENTERA BIO FILES FOR SHELF OF UPTO 9.6 MILLION SHARES BY SELLING STOCKHOLDERS - SEC FILING Source text: (https://bit.ly/2Y3FYIV) Further company coverage:
Reuters · 06/05/2020 21:21
BRIEF-Entera Bio Reports Q1 Loss Per Share Of $0.16
* ANNOUNCES INTERIM BIOMARKER DATA FROM PHASE 2 CLINICAL TRIAL OF EB613 AND FIRST QUARTER 2020 FINANCIAL RESULTS
Reuters · 05/21/2020 10:49
BRIEF-Entera Bio Announces Financial And Operating Results For The Fourth Quarter And Year Ended December 31, 2019
* ENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019
Reuters · 03/26/2020 10:34
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ENTXW. Analyze the recent business situations of ENTERA BIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.07%
Key Executives
Chairman/Independent Director
Gerald Lieberman
Chief Executive Officer/Director
Spiros Jamas
Chief Financial Officer
Dana Yaacov-Garbeli
Corporate Executive
Phillip Schwartz
Chief Operating Officer
Hillel Galitzer
Other
Ramesh Ratan
Other
Arthur Santora
Director
Zeev Bronfeld
Director
Sean Ellis
Director
Yeonatan Malca
Director
Yonatan Malca
Director
Ron Mayron
Independent Director
Faith Charles
Independent Director
Gerald Ostrov
Independent Director
Miranda Toledano
No Data
About ENTXW
Entera Bio Ltd is an Israel-based product-focused biotechnology company that specializes in the oral delivery of large molecules and biologics. The Company conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The Company develops drugs for hypoparathyroidism, osteoporosis and bone healing.

Webull offers kinds of Entera Bio Ltd stock information, including NASDAQ:ENTXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ENTXW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ENTXW stock methods without spending real money on the virtual paper trading platform.